Actively Recruiting
Deciphering Mechanisms Underlying Cancer Immunogenicity
Led by Institut Claudius Regaud · Updated on 2025-09-15
1100
Participants Needed
3
Research Sites
676 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors. The study will be conducted on a population of patients with local and/or metastatic malignant solid tumor and who are followed within a standard of care procedure or clinical trial. Patients with any of the following tumor types may be enrolled in the trial: * Head and neck cancer, * Ovarian cancer, * Cervical cancer, * Pre-invasive CIN III cervical cancer (Cervical Intra-epithelial Neoplasia III cervical cancer), * Other solid tumor types (including glioblastoma, NSCLC (Non-small cell lung cancer), anal cancer) Each tumor type will be considered as an independent cohort. For each included patient, biological specimen (tumor sample, blood samples and ascites samples if applicable) will be collected. Study participation of each patient will be 5 years.
CONDITIONS
Official Title
Deciphering Mechanisms Underlying Cancer Immunogenicity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with histologically documented local or metastatic solid malignant tumor (head and neck, ovarian, cervical, and other tumor types including glioblastoma, NSCLC, and anal cancer) or with pre-invasive cervical high grade dysplasia (CIN II or III)
- Age 18 years or older at study entry
- Patient followed within a standard of care procedure or clinical trial
- ECOG Performance status 0-2
- Patient able to participate and willing to give informed consent and comply with study protocol
- Patient affiliated to a Social Health Insurance in France
- Patient may participate in other clinical trials
You will not qualify if you...
- History of positive test for Hepatitis B virus, Hepatitis C virus, Immunodeficiency Virus (HIV), or Hanta virus
- Any condition contraindicating blood sampling (including Hemoglobin less than 8 g/dl)
- Patient is pregnant or breastfeeding
- Psychological, familial, geographic, or social situation that impairs informed consent or study compliance, as judged by investigator
- Patient deprived of freedom by administrative or legal decision or under guardianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Hopital Larrey
Toulouse, France, 31059
Actively Recruiting
2
Hopital Rangueil
Toulouse, France, 31059
Actively Recruiting
3
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France
Actively Recruiting
Research Team
A
Alejandra MARTINEZ
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here